1. Zhou M, Wu YC, Li HW, Zha XJ. MicroRNA-144: A novel biological marker [and] potential therapeutic target in human solid cancers. J Cancer. 2020;11(22):6716-6726.
2. Zhang L, Wu YC, Wu J, Zhou M, Li DP, Wan XF, Jin F, Wang YN, Lin W, Zha XJ, Liu YH. KLF5-mediated COX2 upregulation contributes to tumorigenesis driven by PTEN deficiency. Cell Signal. 2020;10976.
3. Wang YN, Tang SS, Wu YC, Wan XF, Zhou M,Li HW,Zha XJ. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical f[or] tum[or] growth in tuberous sclerosis complex. IUBMB life. 2020;72(5):965–977.
4. Zhang CC, Wan XF, Tang SS, Li K, Wang YN, Liu YH, Sha Q, Zha XJ, Liu Y. miR-125b-5p/STAT3 Pathway Regulated by mTORC1 Plays a Critical Role in Promoting Cell Proliferation [and] Tum[or] Growth. J Cancer. 2020;11(4):919-931.
5. Jin FQ, Jiang KG, Ji S, Wang L, Ni ZF, Huang FQ, Li CJ, Chen RR, Zhang HB, Hu ZD, Zha XJ. Deficient TSC1/TSC2-complex Suppression of SOX9-Osteopontin-AKT Signaling Cascade Constrains Tum[or] Growth in Tuberous Sclerosis Complex. Hum Mol Genet. 2017;26(2):407-19.
6. Wang L, Ni ZF, Liu YJ, Ji S, Jin FQ, Jiang KG, Ma JF, Ren CP, Zhang HB, Hu ZD, Zha XJ. Hyperactivated mTORC1 downregulation of FOXO3a/PDGFRα/AKT cascade restrains tuberous sclerosis complex-associated tum[or] development. Oncotarget. 2017;8(33):54858-72.
7. Ji S, Lin W, Wang L, Ni ZF,Jin FQ, Zha XJ, Fei GH. Combined Targeting of mT[or] [and] Akt Using Rapamycin [and] MK-2206 in The Treatment of Tuberous Sclerosis Complex. J Cancer. 2017;8(4):555-62.
8. Li HW, Jin FQ, Jiang KG, Ji S, Wang L, Ni ZF, Chen X, Hu Z, Zhang H, Liu YH, Qin YD, Zha XJ. mTORC1-mediated downregulation of COX2 restrains tum[or] growth caused by TSC2 deficiency. Oncotarget. 2016 May 10;7(19):28435-47.
9.Hu ZD, Wang Y, Huang FQ, Chen RR, Li CJ, Wang F, Goto J, Kwiatkowski DJ, Wdzieczak-Bakala J, Tu PF, Liu JM, Zha XJ, Zhang HB. Brain-expressed X-linked 2 Is Pivotal f[or] Hyperactive Mechanistic Target of Rapamycin (mTOR)-mediated Tumorigenesis. J Biol Chem. 2015;290(42):25756-65.
10. Zha XJ, Hu ZD, Ji S, Jin FQ, Jiang KG, Li CJ, Zhao P, Tu ZZ, Chen XG, Di LJ, Zhou HS, Zhang HB. NFκB up-regulation of glucose transporter 3 is essential f[or] hyperactive mammalian target of rapamycin-induced aerobic glycolysis [and] tum[or] growth. Cancer Lett. 2015;359(1):97-106.
11. Zha XJ, Wang F, Wang Y, He S, Jing Y, Wu X, Zhang H. Lactate Dehydrogenase B Is Critical f[or] Hyperactive mTOR-Mediated Tumorigenesis. Cancer Res. 2011;71(1):13-8.
12. Zha XJ, Sun Q, Zhang HB. mT[or] upregulation of glycolytic enzymes promotes tum[or] development. Cell Cycle. 2011;10(7):1015-6.
13. Zha XJ, Hu ZD, He SZ, Wang F, Shen HX, Zhang HB. TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade. Caner Lett. 2011;313(2):211-7.